MedTrace Logo

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

NCT00750152 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2013-04-22

Study results available
· View outcomes & findings →

Summary

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.

Conditions

  • Tinea Cruris
  • Jock Itch

Interventions

DRUG

NAFT-500

topical cream application up to 4 weeks

DRUG

Placebo

placebo cream applied for up to 4 weeks

Sponsors & Collaborators

  • Merz North America, Inc.

    lead INDUSTRY

Principal Investigators

  • Lawrence Parish, MD · Paddington Testing Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-08-31
Completion
2010-02-28

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750152 on ClinicalTrials.gov